NCT00147316View on ClinicalTrials.gov

Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke

PHASE3CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

April 30, 2002

Study Completion Date

September 30, 2003

Conditions
Cerebral InfarctionBrain Ischemia
Interventions
DRUG

Alteplase

0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour

Trial Locations (1)

565-8565

National Cardiovascular Center, Suita

Sponsors
All Listed Sponsors
collaborator

Kyowa Hakko Kogyo Co., Ltd.

INDUSTRY

lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY